QQQ   431.84 (+0.18%)
AAPL   169.76 (-1.70%)
MSFT   416.30 (+0.64%)
META   503.30 (+0.61%)
GOOGL   154.79 (-0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   871.25 (+1.31%)
AMD   163.25 (+1.83%)
NIO   3.81 (-2.06%)
BABA   69.79 (-1.18%)
T   16.07 (-1.05%)
F   12.17 (-0.49%)
MU   121.21 (-0.13%)
GE   155.45 (+1.14%)
CGC   6.96 (-0.29%)
DIS   114.27 (+1.17%)
AMC   2.74 (+10.93%)
PFE   25.86 (-0.19%)
PYPL   64.03 (+0.82%)
XOM   118.84 (-0.70%)
QQQ   431.84 (+0.18%)
AAPL   169.76 (-1.70%)
MSFT   416.30 (+0.64%)
META   503.30 (+0.61%)
GOOGL   154.79 (-0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   871.25 (+1.31%)
AMD   163.25 (+1.83%)
NIO   3.81 (-2.06%)
BABA   69.79 (-1.18%)
T   16.07 (-1.05%)
F   12.17 (-0.49%)
MU   121.21 (-0.13%)
GE   155.45 (+1.14%)
CGC   6.96 (-0.29%)
DIS   114.27 (+1.17%)
AMC   2.74 (+10.93%)
PFE   25.86 (-0.19%)
PYPL   64.03 (+0.82%)
XOM   118.84 (-0.70%)
QQQ   431.84 (+0.18%)
AAPL   169.76 (-1.70%)
MSFT   416.30 (+0.64%)
META   503.30 (+0.61%)
GOOGL   154.79 (-0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   871.25 (+1.31%)
AMD   163.25 (+1.83%)
NIO   3.81 (-2.06%)
BABA   69.79 (-1.18%)
T   16.07 (-1.05%)
F   12.17 (-0.49%)
MU   121.21 (-0.13%)
GE   155.45 (+1.14%)
CGC   6.96 (-0.29%)
DIS   114.27 (+1.17%)
AMC   2.74 (+10.93%)
PFE   25.86 (-0.19%)
PYPL   64.03 (+0.82%)
XOM   118.84 (-0.70%)
QQQ   431.84 (+0.18%)
AAPL   169.76 (-1.70%)
MSFT   416.30 (+0.64%)
META   503.30 (+0.61%)
GOOGL   154.79 (-0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   871.25 (+1.31%)
AMD   163.25 (+1.83%)
NIO   3.81 (-2.06%)
BABA   69.79 (-1.18%)
T   16.07 (-1.05%)
F   12.17 (-0.49%)
MU   121.21 (-0.13%)
GE   155.45 (+1.14%)
CGC   6.96 (-0.29%)
DIS   114.27 (+1.17%)
AMC   2.74 (+10.93%)
PFE   25.86 (-0.19%)
PYPL   64.03 (+0.82%)
XOM   118.84 (-0.70%)
Free Trial

Dr. Martens (DOCS) Stock Forecast & Price Target

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)
Free DOCS Stock Alerts
GBX 67
-27.95 (-29.44%)
(As of 05:07 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider Trades

Dr. Martens Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

GBX 177.50
High ForecastGBX 180
Average ForecastGBX 177.50
Low ForecastGBX 175
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 177.50GBX 177.50GBX 178.33GBX 265
Get Dr. Martens Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.

DOCS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DOCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dr. Martens Stock vs. The Competition

TypeDr. MartensConsumer Cyclical Companies
Consensus Rating Score
2.50
2.48
Consensus RatingModerate BuyHold
News Sentiment RatingPositive News
Neutral News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/5/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweightGBX 175+30.50%
5/30/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeSector PerformGBX 230 ➝ GBX 180+18.66%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:45 PM ET.

DOCS Price Target - Frequently Asked Questions

What is Dr. Martens's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Dr. Martens stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for DOCS. The average twelve-month price prediction for Dr. Martens is GBX 177.50 with a high price target of GBX 180 and a low price target of GBX 175. Learn more on DOCS's analyst rating history.

Do Wall Street analysts like Dr. Martens more than its competitors?

Analysts like Dr. Martens more than other Consumer Cyclical companies. The consensus rating for Dr. Martens is Moderate Buy while the average consensus rating for consumer cyclical companies is Hold. Learn more on how DOCS compares to other companies.

Does Dr. Martens's stock price have much upside?

According to analysts, Dr. Martens's stock has a predicted upside of 24.21% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (LON:DOCS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency